Pharma — India Trademark Cases
245 decisions indexed
Page 7 of 9 · 245 total
Mr Pramod Hegde (M/S Meditek India) v.M/S Indchemie Health Specialities Pvt. Ltd.
The Karnataka High Court dismissed a writ petition challenging the Intellectual Property Appellate Board's decision to deny trademark registration. The dispute centered on whether 'Z-CAL' (Petitioner) was deceptively similar to 'ZECAL' (Respondent). Applying established tests for deceptive similarity, the court found that despite minor spelling differences, the marks were phonetically and visually similar, especially within the pharmaceutical industry where buyers rely heavily on pronunciation. Consequently, the court upheld the prior user's rights, preventing the registration of the petitioner's mark.
Unimed Technologies Ltd. v.M/s Eyekare Kilitch Ltd.
The Madras High Court dismissed Original Side Appeals filed by Unimed Technologies Ltd. and Sun Pharmaceutical Industries Limited against a prior order dismissing their injunction application. The court found that the mark 'TOBA', being derived from the generic chemical term Tobramycin, was publici juris. Furthermore, the court noted factual dissimilarities in color schemes and symbols between the products, concluding there was no prima facie case of passing off or consumer confusion, especially since both drugs are sold under prescription by specialized physicians.
Macleods Pharmaceuticals Ltd. v.Procare Laboratories Pvt. Ltd.
The Delhi High Court ruled in favor of Macleods Pharmaceuticals, finding that Procare Laboratories was engaging in passing off by using the name 'Procare' as part of its corporate identity. The court emphasized that for a passing-off action, trademark registration is not essential; rather, prior use and established goodwill are key. Given the defendant's deliberate absence from court proceedings, the court also awarded punitive damages to deter dishonest conduct.
Smithkline Beecham Plc. v.Sunil Sarmalkar
The Delhi High Court dismissed the suit filed by Smithkline Beecham Plc. against Sunil Sarmalkar concerning alleged infringement and passing off of trademarks PARAMAX and PANAMAX, as well as copyright infringement related to a 'Swirl device.' The court emphasized that mere trademark registration is insufficient; the plaintiff must prove actual use and sales to establish distinctiveness and proprietary rights. Furthermore, the court held that the swirl pattern was likely a design element for passing off purposes rather than an original artistic work qualifying for copyright protection.
Merck Kgaa v.Galaxy Hompro And Anr
The Delhi High Court dismissed Merck Kgaa's appeal against the Intellectual Property Appellate Board (IPAB) decision, upholding the registration of the trademark 'RECIBION'. The court found no deceptive similarity between 'CEBION' and 'RECIBION', emphasizing that the common suffix 'BION' is widely used in the pharmaceutical industry. Crucially, the judgment noted the petitioner's lack of recent use of its mark and applied the strict test for confusion, concluding that the marks were sufficiently distinct.
Ranbaxy Laboratories Limited v.M/S Intas Pharmaceuticals Ltd.
The Delhi High Court addressed a passing off suit filed by Ranbaxy Laboratories against Intas Pharmaceuticals regarding the alleged similarity between their drug trademarks, 'NIFTRAN' and 'NIFTAS'. While the plaintiff sought an interim injunction, the court did not grant a blanket injunction. Instead, it directed the defendant to maintain complete accounts of sales and profits from the product sold under 'NIFTAS', and imposed specific restrictions on packaging types used by the defendant pending further proceedings.
The Himalaya Drug Company & Ors. v.Surjit Singh Sial & Anr.
The Delhi High Court ruled in favor of The Himalaya Drug Company, granting a permanent injunction against the defendant's website for trademark infringement, passing off, and copyright violation. The court found that the defendants were unauthorizedly selling and promoting Himalaya products while creating a false impression of being authorized dealers. Furthermore, the parties settled on damages, with the defendants agreeing to pay Rs. 30,000/- to the plaintiffs.
Apex Laboratories Pvt. Ltd. v.Apex Formulations Pvt. Ltd.
The Madras High Court addressed an application seeking a stay in a trademark infringement suit. While the applicant argued for a stay pending opposition proceedings, the court determined that since the original suit was filed under the older Trade and Merchandise Marks Act, 1958, the relevant provisions applied. The court framed an issue questioning the validity of the plaintiff's trade mark registration and adjourned the case to allow the defendant time to comply with statutory requirements regarding challenging the trademark's validity.
Glaxo Group Ltd. v.Sunlife Sciences Pvt. Ltd.
The Delhi High Court granted an ad interim injunction in favor of Glaxo Group Ltd. against Sunlife Sciences Pvt. Ltd. regarding trademark infringement. The court found that the defendant's use of deceptively similar names (B-NATE-C, CORSUN, ZEETAK) for pharmaceutical products was likely to cause consumer confusion with the plaintiffs' well-known brands (BETNOVATE, CROCIN, ZINETAC). Given the public interest in preventing the sale of spurious drugs, the court emphasized that prima facie evidence and balance of convenience favored restraining the defendant until the final trial.
Nne Pharmaplan India Ltd. v.M/S Cgmp Pharmaplan Pvt. Ltd. & Ors.
The Delhi High Court dismissed Nne Pharmaplan India Ltd.'s suit seeking permanent injunction against M/S Cgmp Pharmaplan Pvt. Ltd., which alleged passing off and infringement of its trade name 'PHARMAPLAN'. The court found that despite both companies operating in the pharmaceutical consulting sector, the names were sufficiently distinct ('NNE' vs. 'cGMP') to prevent customer confusion. Furthermore, the plaintiff failed to establish a prima facie case or irreparable loss, especially given their own inaction against other entities using similar terms.
Glaxo Group Ltd. v.Union Of India & Ors.
Glaxo Group Ltd. challenged the Intellectual Property Appellate Board's (IPAB) dismissal of its trademark registration appeal for 'VOLMAX.' The Delhi High Court intervened, finding that the IPAB had failed to properly consider key legal issues regarding deceptive similarity and the concept of a family of trademarks. Consequently, the High Court set aside the IPAB's order, restoring Glaxo's appeal to be decided afresh on all merits.
M/S Alkem Laboratories Ltd. v.Mega International (P) Ltd.
The Delhi High Court dismissed M/S Alkem Laboratories Ltd.'s appeal against a judgment that rejected its claim of passing off regarding the trademark 'GEMCAL'. The court found insufficient evidence to establish Alkem as the proprietor or prior user, noting that both parties were concurrent users. Furthermore, the court observed no instances of consumer confusion and noted significant differences in sales figures, concluding that Alkem's claims were unsubstantiated.
Uas Pharmaceuticals Pty.Ltd. v.Ajantha Pharma Limited
The Madras High Court dismissed an appeal filed by Uas Pharmaceuticals, which sought an interim injunction against Ajantha Pharma regarding the use of the trade name 'SUNSTOP'. The court found that despite the appellant's international reputation, they had not established their mark in India. Crucially, the respondent was found to be first in the Indian market with a similar product, leading the court to uphold the denial of the injunction based on the balance of convenience and prima facie evidence.
M/S Bal Pharma Ltd. v.M/S Glenmark Pharmaceutical Ltd.
The Madras High Court dismissed a civil revision petition filed by M/S Bal Pharma Ltd against an order passed by the Intellectual Property Appellate Board (IPAB). The IPAB had granted a stay on the registration of a trade mark application, which was sought by Glenmark Pharmaceutical Ltd. The High Court found the IPAB's decision to be balanced and reasonable, noting that allowing immediate registration would create significant complications for the parties involved. Consequently, the court directed the IPAB to expedite the hearing and final disposal of the original appeal.
Macleods Pharmaceuticals Ltd. v.Alembic Limited
Macleods Pharmaceuticals Ltd. challenged an ex-parte injunction passed by the lower court against it, which restrained the use of its trade mark GEMIMAC due to alleged similarity with Alembic Limited's reputed trade mark GERIMAC. The appellant argued that the injunction was granted without issuing prior notice or recording adequate reasons, violating procedural requirements under the Code of Civil Procedure. The Gujarat High Court admitted the appeal and intervened, restricting the scope of the injunction until a proper hearing could take place.
Paras Pharmaceuticals Ltd. v.Ranbaxy Laboratories Ltd.
Paras Pharmaceuticals Ltd. filed a suit against Ranbaxy Laboratories Ltd., alleging that Ranbaxy was using negative advertisement and TV commercials for its pain reliever VOLINI to disparage Paras's popular product, MOOV. The court found that Ranbaxy's commercial depicted a box identical in artistic work and color scheme to MOOV, subtly suggesting that MOOV was inferior. Consequently, the Gujarat High Court allowed the appeal and directed Ranbaxy to change its packaging colors and cease using the appellant's artwork.
Reddy Pharmaceuticals Ltd. v.Dr. Reddy'S Laboratories Ltd.
The Delhi High Court dismissed an appeal, upholding the injunction granted against Dr. Reddy's Laboratories Ltd. The case centered on whether the defendant was passing off its products by using a deceptively similar name and logo ('Reddy') that accrued goodwill to the plaintiff's established trademark 'Dr. Reddy'. The court affirmed that while the defendant had initially been an agent, its subsequent entry into manufacturing finished dosage forms under the disputed brand constituted infringement. The judgment emphasized that even if alternative views were possible on the facts, appellate courts should not interfere with a trial court's properly exercised discretion. This ruling reinforces the importance of protecting established trade names and goodwill in the pharmaceutical sector.
Ayurherbs Pharmaceuticals Private Limited v.Three-N-Products Private Limited
The Delhi High Court ruled in favor of Ayurherbs Pharmaceuticals, finding that Three-N-Products Private Limited was engaging in passing off by using the name 'Ayur' in its corporate identity. Despite arguments regarding product differences and derivation from Ayurveda, the court held that the use of the suffix 'Ayur Herbs Pharmaceuticals Private Limited' was likely to confuse the ordinary purchaser. This judgment reinforces the principle that trademark infringement can occur even if the goods are not identical, provided there is a likelihood of deception.
Sun Pharmaceutical Industries Limited v.Cipla Limited
The Bombay High Court rejected Sun Pharmaceutical Industries Limited's application for an interim injunction against Cipla Limited regarding the use of the trade mark 'Graniset'. Despite the similarity in marks and their use in treating nausea related to chemotherapy, the court found that the plaintiff lacked a prima facie proprietary right in the mark. The judgment highlighted the importance of prior user rights versus registration, while also noting the plaintiff's failure to provide supporting medical evidence for potential consumer confusion.
German Remedies Ltd. v.Commissioner Of Central Excise
German Remedies Ltd. challenged the Commissioner's decision regarding the classification and duty rate for its Acetyl Salicylic Acid (ASA) tablets. The dispute centered on whether the product, which was previously classified as a patent/proprietary medicament due to branding, should be treated as a generic product after dropping the trade mark. The Tribunal found that 'ASA' is merely an abbreviation of the chemical name and not a proprietary designation.
Cadila Healthcare Limited v.Lupin Laboratories Ltd.
This Gujarat High Court judgment addressed a critical jurisdictional dispute regarding trademark infringement suits. Cadila Healthcare challenged the jurisdiction of the Fast Track Court, arguing that Section 134 of the Trade Marks Act mandates such cases be heard only by a District Court. The Court ultimately rejected this contention, ruling that due to the structural provisions linking Fast Track Courts and Additional Judges to the District Judge's cadre, the Fast Track Court possesses the necessary jurisdiction to try the suit.
Glaxosmithkline Pharmaceuticals v.Theodar Laboratories Private Limited
The Delhi High Court ruled in favor of Glaxosmithkline Pharmaceuticals, granting a permanent injunction against Theodar Laboratories Private Limited for infringing on its trademarked product's packaging. The court found that the defendant's carton was a 'slavish imitation' of the plaintiff's distinctive color scheme and layout, which would mislead innocent consumers purchasing animal supplements. This judgment reinforces the protection afforded to trade dress in the pharmaceutical/feed supplement sector.
Pfizer Products Inc. v.Mr. Altamash Khan And Anr.
The Delhi High Court ruled in favor of Pfizer Products Inc., granting an interim order for the transfer of the domain name 'viagra.in' from the defendant to the plaintiff. The court recognized that a domain name is a valuable asset entitled to protection similar to a trademark, especially when it creates confusion or constitutes cyber squatting. This decision underscores the critical importance of securing digital real estate for major brands in the e-commerce era.
Allergan Inc. v.Chetana Pharmaceuticals
The plaintiff filed a suit for passing off against the defendant regarding the identical mark "Oxyline" used for medicinal products (eye drop vs. nasal drop). The court examined the claims of senior user status by both parties and the potential confusion arising from using similar marks on vital medicines.
Medley Pharmaceuticals Ltd. v.Khandelwal Laboratories Ltd.
The Bombay High Court dismissed the plaintiff's motion seeking an interim injunction in a passing off suit. The court found that the trade marks, including those with the prefix 'CEF,' are commonly used across the pharmaceutical industry. Given the prevalence of similar prefixes and suffixes derived from chemical compounds like Cefixime, the court held that the plaintiff failed to establish exclusivity or reputation for their mark, thus denying the injunction.
G.D. Searle Llc And Ors. v.Maiden Pharmaceuticals Ltd.
The Delhi High Court addressed applications for ad interim injunction concerning the anti-diarrhea drug LOMOTIL. The court found considerable merit in the plaintiffs' claims that the defendants' products (MICROTIL and MONOTIL) were deceptively similar to LOMOTIL, particularly regarding trade dress, packaging, and color scheme. However, instead of outright banning the defendant's trademarks, the court modified the existing injunctions. The defendants are permitted to market their products under their respective names, provided they significantly alter their product's visual appearance (trade dress) to avoid consumer confusion.
Torrent Pharmaceuticals Limited v.Reddy'S Laboratories Limited
Torrent Pharmaceuticals Limited filed an application for the trade mark 'DOPAMINE'. Reddy'S Laboratories Limited opposed this registration, arguing that 'DOPAMINE' was descriptively similar to their existing mark 'DOPAMET' and was a non-proprietary generic name for a chemical compound. The IPAB ultimately dismissed the appeal, agreeing with the opposition that the mark failed to meet the requirements of Section 9.
Milmet Oftho Industries & Ors. v.Allergan Inc.
The Supreme Court addressed a passing off dispute concerning the pharmaceutical mark 'OCUFLOX' between an Indian company and a multinational corporation. While acknowledging the global nature of medicine and the potential harm from confusion, the court emphasized that the ultimate test remains who was first in the market. The judgment directed the trial court to continue the injunction while expediting the suit for final determination based on evidence regarding prior use.
Pfizer Ireland Pharmaceuticals v.Intas Pharmaceuticals And Anr.
The Delhi High Court granted a temporary injunction in favor of Pfizer Ireland Pharmaceuticals against Intas Pharmaceuticals, finding that the defendants' use of the mark 'LIPICOR' was deceptively and confusingly similar to the plaintiff's globally reputed trademark 'LIPItor'. Despite the plaintiff not yet having entered the Indian market, the court recognized the trans-border reputation of LIPItor. The judgment emphasized the need for a stricter approach in pharmaceutical cases due to the potential disastrous effects on consumer health, thereby protecting the goodwill associated with the original brand.
Exphar SA v.Eupharma Laboratories Ltd.
This Supreme Court judgment addressed a dispute concerning the trademark 'Maloxine' and its distinctive packaging design. The appellants, claiming ownership of the copyright and trademark, sued the respondents for passing off and copyright infringement related to the malaria medicine. A key legal challenge was whether the Delhi High Court had territorial jurisdiction over the matter. The court ultimately ruled that the receipt of a cease and desist notice within the jurisdiction was sufficient to invoke the court's authority.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.